Wegovy HD becomes the fourth approval under the FDA's priority voucher pilot

The FDA approved Wegovy HD, a higher 7.2 mg dose of semaglutide injection from Novo Nordisk, on March 19, 2026, for weight loss and long-term maintenance of weight loss in certain adults. The agency said the decision came just 54 days after the application was filed and was the fourth approval under the Commissioner's National Priority Voucher (CNPV) pilot program ^[1].

The new dose is cleared to reduce excess body weight and maintain that reduction long term in adults with obesity, or overweight with at least one weight-related condition ^[1]. It joins an existing US Wegovy lineup that includes once-weekly injections at 1.7 mg and 2.4 mg and the 25 mg once-daily pill ^[3]. The 7.2 mg dose is already approved in the EU and UK ^[3]. Novo Nordisk said a US launch in a single-dose pen was expected in April 2026 ^[3].

"The new FDA is moving with unprecedented efficiency on products that advance national priorities," FDA Commissioner Martin Makary said. "Today's approval is another demonstration of what the FDA can accomplish when we try bold new things" ^[1].

What the trials showed

The approval rests on the phase 3 STEP UP program. In STEP UP, 1,407 adults with obesity were randomly assigned to semaglutide 7.2 mg, 2.4 mg or placebo plus lifestyle changes over 72 weeks. The 7.2 mg group lost an average of 18.7% of body weight versus 3.9% with placebo, and 31.2% lost at least 25% ^[3]. Novo Nordisk's own news release described the higher dose as delivering 20.7% mean weight loss, and company CEO Mike Doustdar said it provides "even greater weight loss of approximately 21%" ^[3]. The sources give both figures without explaining the difference, so the exact average a person might expect is not settled in the material available here.

In STEP UP T2D, which enrolled about 512 adults with obesity and type 2 diabetes, the 7.2 mg dose produced 13.2% mean weight loss versus placebo, and 21.3% of patients lost 20% or more ^[3]. The FDA noted that in people with both obesity and type 2 diabetes, the higher dose lowered hemoglobin A1C about the same as the lower dose ^[1].

Side effects were mostly gastrointestinal — nausea, vomiting, diarrhea, constipation and abdominal pain ^[1]. The FDA also flagged altered skin sensation, described as sensitivity, pain or burning, which was common, occurred more often at the higher dose, and generally resolved on its own or with a dose reduction. The agency said it is conducting further investigations into that reaction ^[1]. In STEP UP T2D, this dysesthesia was reported in 18.9% of patients on 7.2 mg, 4.9% on 2.4 mg and 0% on placebo ^[3]. Wegovy carries a boxed warning about thyroid C-cell tumors seen in rodent studies and is not for people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[1].

Why it matters for patients

For people who have not lost as much weight as hoped on the 2.4 mg dose, the 7.2 mg option adds a higher rung within the same drug class before other steps such as surgery are considered ^[3]. The trade-off visible in the data is more gastrointestinal side effects and noticeably more skin-sensation complaints at the higher dose, with no added blood sugar benefit in people who also have type 2 diabetes ^[1][3].

The approval pathway itself is also part of the story. CNPV vouchers give companies rolling review and enhanced communication with the FDA to shorten review times for products the agency ties to national health priorities, including affordability and domestic manufacturing ^[1]. Eli Lilly's orforglipron pill, marketed as Foundayo, was approved April 1, 2026 under the same program ^[2]. STAT reported that the voucher program has been controversial, with agency insiders saying it has been a vehicle for political interference, and that Lilly received its voucher as part of a deal with the White House to lower obesity drug prices in certain settings ^[2].

What happens next

The FDA said it will hold a public hearing in June to gather feedback on the voucher program, with a Federal Register notice to follow ^[1]. Pricing and insurance coverage for Wegovy HD are not described in these sources. For the pill competition, Lilly said on April 1 it will sell Foundayo at up to $299 a month in cash if patients continually renew their prescription, matching Novo's cash price for the Wegovy pill ^[2].